Frontotemporal Lobar Dementia (FTLD) Archives

Yumanity and Proteostasis Merge

ALS, Business, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Frontotemporal Dementia (FTD), Frontotemporal Lobar Dementia (FTLD), Lewy Body Dementia (LBD), Mergers, Neurodegenerative Diseases, Parkinson’s disease, Product Pipelines, Protein Misfolding

Cambridge, Massachusetts-based Yumanity Therapeutics and Boston-based Proteostasis Therapeutics announced plans to merge. The combined company will operate after the deal as Yumanity Therapeutics, and will focus on protein misfolding and neurodegenerative diseases.

August 24, 2020/by BioSpace

Yumanity and Merck Ink Deal for Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS), Brain Disorders, Business, Deals, Frontotemporal Lobar Dementia (FTLD), Licensing, Neurodegenerative Diseases

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD).

June 24, 2020/by BioSpace